Hadassah Graduate Designs Programs That Decrease Death from HIV/AIDS and TB
Benson Ulo, a 2003 graduate of the
International Masters of Public Health Program at the Hadassah-Hebrew
University Braun School of Public Health and Community Medicine, applauds his
education for providing him with a “flexible think tank,” where students are
equipped to shape public health care worldwide.
struggled to gain admittance to medical school, Mr. Ulo found himself forced to
interrupt his education. He took on odd jobs at construction sites, just to
survive. Three years later, he was fortunate to get a sponsor, which made it
possible for him to return to academia to study public health. He subsequently
received a scholarship to attend the IMPH program in Jerusalem. This was “an opportunity of a lifetime,” he
says, “and has led to multiple rewards in my life.”
Hadassah enables women to expand their horizons, take charge of their lives and provides opportunities to study Judaism, Zionism, Jewish history, Hebrew, literature and culture.
international Medical Corps, his employer since 2004, Mr. Ulo says, his IMPH
education has enabled him to design and implement HIV/AIDS and TB programs that
have helped thousands of people, with both prevention and treatment in remote
areas of his country. Mr. Ulo is currently the director of an HIV/AIDS and TB
program in local prisons which, he reports, has greatly improved the health of
inmates, bringing down the TB death rate from about 40 percent to zero!
shares his work experiences at international conferences and, as a result,
believes he influences program design in many other countries.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>